Piper Sandler raised the firm’s price target on Novocure (NVCR) to $42 from $28 and keeps an Overweight rating on the shares. The firm thinks the catalyst path for Novocure shares screens more favorably for medical technology investors that can better handicap upcoming “medtech-like” milestones for the company, including new indication commercialization, regulatory submission and approvals, and securing payer coverage. Piper introduced estimates through 2028 and highlights the company’s improved execution for four consecutive quarters.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVCR:
- Novocure price target raised to $38 from $30 at H.C. Wainwright
- Novocure price target raised to $33 from $28 at Leerink
- Morning Movers: Intel climbs following retirement of CEO Pat Gelsinger
- NovoCure’s TTFields Therapy Shows Promise in PANOVA-3 Trial
- Zai Lab, Novocure announce PANOVA-3 trial met primary endpoint